Keytruda
MSD announces phase 2 results for tulisokibart in moderate to severe hidradenitis suppurativa
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
Moderna’s updated COVID-19 mRNA vaccine approved by MHRA
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
BriaCell advances personalised skin cancer immunotherapy vaccine candidate
Around 112,000 new cases of skin cancer will be diagnosed in the US in 2026
MSD and Moderna announce potential new vaccine for melanoma
The mRNA-based therapy, used with Keytruda, is designed specifically for each patient
Cases of skin cancer set to reach 263,000 in 2035 according to new report
The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe
Moderna appoints Piyali Mukherjee as Head of Medical Affairs, Europe and Middle East
Mukherjee has previously held senior leadership roles at Moderna and GSK
Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer
The combination treatment showed a 35% reduction in the risk of disease progression
Moderna and Merck announce data from melanoma combination therapy study
Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths
MSD receives NICE recommendation for Keytruda in advanced endometrial cancer
More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK
Merck unveils $3bn cost-cutting plan to support pipeline and new product launches
A new restructuring programme has been approved to support the initiative
Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP
Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1
Moderna shares positive phase 3 results for mRNA flu vaccine candidate
More than 600,000 people in the US were hospitalised due to flu-related illness last year